Latest news
argenx reports half year 2020 financial results and provides second quarter business update
Reaching Patients Through
Immunology Innovation
The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.
The infinity sign symbolizes our commitment to science and patients; it has no bounds.
Patients
Innovation
Where we operate
Together We Discover
We know that leaps in progress will come from collaboration and incorporating innovation into every step. We embrace the power of the collective – together we are better.
Our Discoveries
At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies.
Pipeline
Product Candidates
Our proprietary portfolio is focused on first-in-class product candidates engineered in collaboration with our academic partners to help translate immunology breakthroughs into medicines.
Our Pride
Efgartigimod
FcRn
We are investigating efgartigimod for the treatment of myasthenia gravis and other severe autoimmune diseases.
Designed to block FcRn and reduce IgGs, efgartigimod could be a rational approach to treating diseases where IgG antibodies are pathogenic or disease-causing.
Cusatuzumab
CD70
We have a global collaboration and licensing agreement with Janssen R&D to develop and commercialize cusatuzumab for the treatment of hematological malignancies.
Cusatuzumab is designed with multiple mechanisms of action to kill malignant cells such as leukemia blasts and stem cells.